FDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid Patients
May 11 2022 - 7:43AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. and Incyte Corp. on Wednesday said the U.S.
Food and Drug Administration granted full approval for the use of
their arthritis drug Olumiant for the treatment of certain
hospitalized patients with Covid-19.
The companies said the approval covers hospitalized adults
needing supplemental oxygen, noninvasive or invasive mechanical
ventilation, or extracorporeal membrane oxygenation, with a
recommended dose of four milligrams a day for 14 days or until
discharge.
Eli Lilly and Incyte said the FDA nod makes Olumiant the first
and only Janus kinase, or JAK, inhibitor cleared for the treatment
of Covid-19 in hospitalized adults needing various degrees of
oxygen support.
The FDA granted emergency-use authorization for Olumiant in
November 2020. That authorization will remain in place for
hospitalized pediatric patients ages 2 through 18, the company
said.
Indianapolis-based Eli Lilly signed an exclusive world-wide
license and collaboration agreement with Incyte, a Wilmington,
Del., biopharmaceutical company, in late 2009 to develop and
commercialize Olumiant and other compounds for inflammatory and
autoimmune diseases.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 11, 2022 07:28 ET (11:28 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jul 2023 to Jul 2024